BHC / Bausch Health Companies Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement  ☐ Definitive Additional Materials  ☐ Soliciting Material Pursuant to § 240.

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

EX-99.(A)(5)(B) Exhibit (a)(5)(B) Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] 877-281-6642 (toll-free) (908) 569-3692 Investor Relations (DURECT Corporation) Media Contact (DURECT Corporation) Sandya von der Weid Michael Fitzhugh LifeSci Advisors LifeSci Communications [email protected] mfitzhugh@lifesc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC. a wholly owned subsidiary of BAUSCH HEALTH AMERICAS, INC. a wholly owned subsidiary of BAUSCH HEALTH COMP

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Bausch Health Companies Inc. (E

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other jurisdiction of incorporation or or

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

EX-99.1 Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] (877) 281-6642 (toll free) (908) 569-3692 Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes LAVAL, QC, August 15, 2025 – Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) (“Bausch Health” or the “Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  ☐ Definitive Proxy Statement  ☐ Definitive Additional Materials  ☐ Soliciting Material Pursuant to § 240.

Letter of Transmittal to Tender Shares of Common Stock DURECT CORPORATION $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, of

EX-99.(a)(1)(B) Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of DURECT CORPORATION at $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate, upon the achievement of specified milestones (m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON

SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC. a wholly owned subsidiary of BAUSCH HEALTH AMERICAS, INC. a wholly owned subsidiary of BAUSCH HEALTH COMPANIES INC. (Names of

Offer to Purchase All Outstanding Shares of Common Stock DURECT CORPORATION $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, o

EX-99.(a)(1)(A) Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of DURECT CORPORATION at $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate, upon the achievement of specified milestones

This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by

EX-99.(a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by the Offer to Purchase, dated as of August 12, 2025, and the related Letter of Transmittal and any amendments or sup

Offer to Purchase All Outstanding Shares of Common Stock DURECT CORPORATION $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, o

EX-99.(a)(1)(E) Exhibit (a)(1)(E) Offer to Purchase All Outstanding Shares of Common Stock of DURECT CORPORATION at $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate, upon the achievement of specified milestones

Notice of Guaranteed Delivery Offer to Purchase All Outstanding Shares of Common Stock DURECT CORPORATION $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive th

EX-99.(a)(1)(C) Exhibit (a)(1)(C) Notice of Guaranteed Delivery for Offer to Purchase All Outstanding Shares of Common Stock of DURECT CORPORATION at $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate, upon the ac

Offer to Purchase All Outstanding Shares of Common Stock DURECT CORPORATION $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, o

EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of DURECT CORPORATION at $1.75 net per share, in cash, plus one non-tradeable contingent value right for each share, which represents the contractual right to receive the pro rata portion, in cash, of two milestone payments of up to $350,000,000 in the aggregate, upon the achievement of specified milestones

Calculation of Filing Fee Tables SCHEDULE TO (Rule 14d-100) DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC. a wholly owned subsidiary of BAUSCH HEALTH AMERICAS, INC. a wholly owned subsidiary of BAUSCH HEALTH COMPANIES

Exhibit 107 Calculation of Filing Fee Tables SCHEDULE TO (Rule 14d-100) DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Compani

As filed with the Securities and Exchange Commission on July 31, 2025

As filed with the Securities and Exchange Commission on July 31, 2025 Registration No.

Filing Fee Table

Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Bausch Health Companies Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common S

Bausch Health Companies Inc. 2025 Employee Stock Purchase Plan, originally filed as Exhibit B to the Company’s Management Proxy Circular and Proxy Statement on Schedule 14A filed on April 2, 2025

Exhibit 99.1 BAUSCH HEALTH COMPANIES INC. 2025 EMPLOYEE STOCK PURCHASE PLAN Section 1. Purpose. This Bausch Health Companies Inc. 2025 Employee Stock Purchase Plan (the “Plan”) is intended to provide employees of Bausch Health Companies Inc. (the “Company”) and the Participating Companies with an opportunity to acquire a proprietary interest in the Company through the purchase of Shares. The Plan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC. a wholly owned subsidiary of BAUSCH HEALTH AMERICAS, INC. a wholly owned subsidiary of BAUSCH HEALTH COMPANIES INC. (Names of Filing

Excerpted transcript of applicable “question and answer” portions of BHC’s Second-Quarter 2025 Earnings Presentation, dated July 30, 2025.

EX-99.1 Exhibit 99.1 The following are excerpts from the transcript of the “question and answer” portion of the Bausch Health Second-Quarter 2025 Earnings Presentation, held on Wednesday, July 30, 2025 from 5:00pm to 5:44 pm ET. * * * Douglas Miehm, Analyst, RBC Dominion Securities, Inc. – Question: Well, yeah, I did want to just ask on DURECT. Is there any additional information you can provide o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC. a wholly owned subsidiary of BAUSCH HEALTH AMERICAS, INC. a wholly owned subsidiary of BAUSCH HEALTH COMPANIES INC. (Names of

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 30, 2025 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorpo

BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2025 RESULTS

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2025 RESULTS •Second Quarter Consolidated Revenues of $2.53 billion, up 5% on a Reported basis and 4% on an Organic (non-GAAP)1 basis over the prior year period •GAAP Net Income At

Excerpted transcript of applicable portions of BHC’s Second-Quarter 2025 Earnings Presentation, dated July 30, 2025.

EX-99.1 Exhibit 99.1 The following are excerpts from the transcript of the Bausch Health Second-Quarter 2025 Earnings Presentation, held on Wednesday, July 30, 2025 at 5:00pm ET. * * * Tom Appio (Chief Executive Officer): We announced after the quarter that we entered into an agreement to acquire DURECT Corporation, which, if all closing conditions are satisfied and the acquisition closes, will en

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

EX-99.1 Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] 877-281-6642 (toll-free) (908) 569-3692 Investor Relations (DURECT Corporation) Media Contact (DURECT Corporation) Sandya von der Weid Michael Fitzhugh LifeSci Advisors LifeSci Communications [email protected] [email protected] Ba

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): July 29, 2025 Bausch Health C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): July 29, 2025 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DURECT CORPORATION (Name of Subject Company (Issuer)) BHC LYON MERGER SUB, INC. a wholly owned subsidiary of BAUSCH HEALTH AMERICAS, INC. a wholly owned subsidiary of BAUSCH HEALTH COMPANIES INC. (Names of

Press Release, dated July 29, 2025.

EX-99.1 Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] 877-281-6642 (toll-free) (908) 569-3692 Investor Relations (DURECT Corporation) Media Contact (DURECT Corporation) Sandya von der Weid Michael Fitzhugh LifeSci Advisors LifeSci Communications [email protected] [email protected] Ba

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): July 29, 2025 Bausch Health C

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): July 29, 2025 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdictio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 Bausch Health Companies Inc. (Exa

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other jurisdiction of incorporation or orga

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

EX-99.1 Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] (877) 281-6642 (toll free) (908) 569-3692 Bausch Health Announces the Appointment of Two New Members to Its Board of Directors LAVAL, QC, July 24, 2025 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, tod

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 Bausch Health Companies Inc. (Exa

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other jurisdiction of incorporation or orga

Bausch Health Appoints New Chief Accounting Officer

EX-99.1 Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] (877) 281-6642 (toll free) (908) 569-3692 Bausch Health Appoints New Chief Accounting Officer LAVAL, QC, July 10, 2025 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of S

Indenture, dated as of June 26, 2025, by and among Bausch & Lomb Incorporated, Bausch+Lomb Netherlands B.V., the guarantors party thereto, Citibank, N.A., acting as trustee and as notes collateral agent and Citibank, N.A. London Branch, acting as paying agent, registrar, transfer agent and calculation agent.

EX-4.1 Exhibit 4.1 Execution Version BAUSCH & LOMB INCORPORATED BAUSCH+LOMB NETHERLANDS B.V. €675,000,000 SENIOR SECURED FLOATING RATE NOTES DUE 2031 INDENTURE DATED AS OF JUNE 26, 2025 CITIBANK, N.A., AS TRUSTEE AND NOTES COLLATERAL AGENT CITIBANK, N.A., LONDON BRANCH AS PAYING AGENT, REGISTRAR, TRANSFER AGENT AND CALCULATION AGENT TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY

Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

Exhibit 99.1 Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility VAUGHAN, Ontario, June 26, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, tod

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 26, 2025 Bausch Health Companies Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 26, 2025 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation or

Third Amendment to Credit and Guaranty Agreement by and among Bausch + Lomb Corporation, certain subsidiaries of Bausch + Lomb Corporation as subsidiary guarantors, the lenders party thereto and other persons party thereto, JPMorgan Chase Bank, N.A. and Citibank, N.A., dated as of June 26, 2025.

EX-10.1 Exhibit 10.1 Execution Version THIRD AMENDMENT TO CREDIT AND GUARANTY AGREEMENT THIRD AMENDMENT (this “Agreement”), dated as of June 26, 2025, among Bausch + Lomb Corporation, a corporation incorporated under the Canada Business Corporations Act (the “Borrower”), certain subsidiaries of the Borrower, as Subsidiary Guarantors, the 2025 Refinancing Term Lenders (as defined below) party heret

Financial Statements and Exhibits, Other Events

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 18, 2025 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation or

Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

Exhibit 99.1 Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering VAUGHAN, Ontario, June 18, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collective

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 10, 2025 Bausch Health Companies Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 10, 2025 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation or

Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement

Exhibit 99.1 Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement VAUGHAN, Ontario, June 10, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BAUSCH HEALTH COMPANIES INC. (Exact name of registrant as specified in its charter) Bausch Health Companies Inc. (Exact name of registrant a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BAUSCH HEALTH COMPANIES INC. (Exact name of registrant as specified in its charter) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 (State or other jurisdiction of incorporation) (Commission file number) 2150 St. Elzéa

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

Exhibit 1.01 Conflict Minerals Report For the Year ended December 31, 2024 Part I. Introduction This is the Conflict Minerals Report (“Report”) of Bausch Health Companies Inc. (“Bausch Health,” the “Company,” “we,” “our” or “us”) for calendar year 2024, prepared and submitted in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “1934 Act”). Please refer to Ru

Letter Agreement by and among Bausch Health Companies Inc. and John Paulson, dated May 20, 2025.

EX-10.3 Exhibit 10.3 Execution Version [Conformed] DELIVERED BY E-MAIL May 20, 2025 John Paulson Director Dear Mr. Paulson: Letter Agreement Further to the meeting of the board of directors (the BHCI Board) of Bausch Health Companies Inc. (the Company) held yesterday, this letter agreement sets forth certain agreements between you and the Company regarding the matters discussed herein. For good an

Letter Agreement by and among Bausch Health Companies Inc. and Sarah Kavanagh, dated May 20, 2025, originally filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on May 21, 2025, which is incorporated by reference herein.

EX-10.4 Exhibit 10.4 Execution Version [Conformed] DELIVERED BY E-MAIL May 20, 2025 Sarah B. Kavanagh Director Dear Ms. Kavanagh: Letter Agreement Further to the meeting of the board of directors (the BHCI Board) of Bausch Health Companies Inc. (the Company) held yesterday, this letter agreement sets forth certain agreements between you and the Company regarding the matters discussed herein. For g

Letter Agreement by and among Bausch Health Companies Inc., Carl C. Icahn and the persons and entities listed therein, dated May 20, 2025.

EX-10.2 Exhibit 10.2 Execution Version [Conformed] DELIVERED BY E-MAIL May 20, 2025 Brett Icahn Icahn Capital LP 16690 Collins Avenue Penthouse Suite Sunny Isles Beach FL 33160 Dear Mr. Icahn: Supplemental Letter Agreement Further to our discussions and the meeting of the board of directors (the BHCI Board) of Bausch Health Companies Inc. (the Company) held yesterday, this letter agreement sets fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 MAY 20, 2025 Date of report (Date of earliest event reported) Bausch Health Compani

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 MAY 20, 2025 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other jurisdiction of incorpora

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 MAY 9, 2025 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other jurisdiction of incorporat

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 MAY 14, 2025 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorpor

Employment Agreement dated as of June 17, 2024 between Bausch Health Companies Inc. and Aimee Lenar.

Exhibit 10.2 AMENDED AND RESTATED BAUSCH HEALTH COMPANIES INC. EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is hereby entered into as of June 17, 2024 (the “Effective Date”), by and between Bausch Health Companies Inc., a British Columbia corporation (“Bausch Health” or the “Company”), and Aimee Lenar, an individual (the “Executive”) (hereinafter collective

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 30, 2025 Date of report (Date of earliest event reported) Bausch Health Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 30, 2025 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorp

BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2025 RESULTS

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2025 RESULTS •First Quarter Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP)1 basis over the prior year period •GAAP Net Loss Attrib

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240.

Current Report

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): April 14, 2025 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation or

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Bausch Health Companies Inc. (Exact Name of Registrant as S

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation or Organization) (Commission File

Bausch Health Announces Adoption of Shareholder Rights Plan

EX-99.1 Exhibit 99.1 Investor Contact: Garen Sarafian [email protected] (877) 281-6642 (toll free) Media Contact: Katie Savastano [email protected] (908) 569-3692 Bausch Health Announces Adoption of Shareholder Rights Plan LAVAL, QC, April 14, 2025 – Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) (the “Company” or “Bausch Health”) announces today that its board of dir

Shareholder Rights Plan Agreement, dated as of April 14, 2025, by and between Bausch Health Companies Inc. and TSX Trust Company, as rights agent (which includes the Form of Rights Certificate as Schedule A thereto) originally filed as Exhibit 4.1 to the Company’s Registration Statement on Form 8-A, filed on April 15, 2025 (File No. 001-14956), which is incorporated by reference herein.

Exhibit 4.1 SHAREHOLDER RIGHTS PLAN AGREEMENT BETWEEN BAUSCH HEALTH COMPANIES INC. AND TSX TRUST COMPANY Made as of April 14, 2025 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 1.1 Certain Definitions 2 1.2 Currency 16 1.3 Number and Gender 16 1.4 Sections 17 1.5 Statutory References 17 1.6 Calculation of Voting Shares Beneficially Owned 17 1.7 Acting Jointly or in Concert 17 1.8 Generally Accepted A

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 APRIL 8, 2025 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other jurisdiction of incorpor

Indenture, dated as of April 8, 2025, by and among 1261229 B.C. Ltd., Bausch Health Companies Inc., the other guarantors party thereto, The Bank of New York Mellon, as trustee and the notes collateral agents party thereto, originally filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on April 8, 2025, which is incorporated by reference herein.

Exhibit 4.1 1261229 B.C. LTD. 10.000% SENIOR SECURED NOTES DUE 2032 INDENTURE DATED AS OF APRIL 8, 2025 THE BANK OF NEW YORK MELLON, AS TRUSTEE, REGISTRAR AND PAYING AGENT AND THE NOTES COLLATERAL AGENTS PARTY HERETO TABLE OF CONTENTS ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.1 Definitions 1 SECTION 1.2 Other Definitions 45 SECTION 1.3 Rules of Construction 46 ARTICLE 2 THE SE

Credit Agreement, dated as of April 8, 2025, by and among 1261229 B.C. Ltd., 1530065 B.C. Ltd., Bausch Health Companies Inc., the subsidiary guarantors party thereto, JPMorgan Chase Bank, N.A., as administrative agent, and other certain financial institutions, as agents and/or lenders.

Exhibit 10.1 Execution Version CREDIT AND GUARANTY AGREEMENT dated as of April 8, 2025 among BAUSCH HEALTH COMPANIES INC., as the Parent, 1530065 B.C. LTD., as Intermediate Holdco, 1261229 B.C. LTD., as the Borrower, CERTAIN SUBSIDIARIES OF BAUSCH HEALTH COMPANIES INC., as Subsidiary Guarantors, THE FINANCIAL INSTITUTIONS PARTY HERETO, as Lenders and Issuing Banks, JPMORGAN CHASE BANK, N.A., as Ad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 ny20039462x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement  ☐ Definitive Additional Materials  ☐ Soliciting Material Pursuant to § 240.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 25, 2025 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorp

Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] (877) 281-6642 (toll free) (908) 541-3785 Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes LAVAL, QC, March 25, 2025 — Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) (the “Company” or “Bausch Health”) today announced that

Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] (877) 281-6642 (toll free) (908) 541-3785 Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes LAVAL, QC, March 19, 2025 — Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) (the “Company” or “Bau

Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities Transaction is part of a broader refinancing initiative aimed at opportunistically accessing capital markets to address near- and mid-term maturities

Exhibit 99.2 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] (877) 281-6642 (toll free) (908) 541-3785 Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities Transaction is part of a broader refinancing initiative aimed at opportunistically accessing capital markets to address near- and mid

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 19, 2025 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Companies I

Bausch Health Companies Inc. Blackout Policy.

Exhibit 19.1 Bausch Health POLICY NO. DATED PAGE NO 1 of 4 Companies Inc. H.R. Sec. 9-919 July 25, 2023 ISSUED BY: PREPARED BY: Legal Department General Counsel SUBJECT: APPROVED BY: Blackout Periods Board of Directors BLACKOUT POLICY A.PURPOSE The purpose of this Blackout Policy (the “Policy”) is to prohibit trading in the Securities of Bausch Health Companies Inc. during certain periods where th

Bausch Health Companies Inc. Insider Trading Policy.

Exhibit 19.2 Bausch Health Companies Inc. POLICY NO. EFFECTIVE DATE PAGE NO 1 of 7 H.R. Sec. 9-911 July 23, 2024 ISSUED BY: PREPARED BY: Legal Department General Counsel SUBJECT: APPROVED BY: Insider Trading and Reporting Board of Directors INSIDER TRADING POLICY A.PURPOSE The purpose of this Insider Trading Policy (the “Policy”) is to explain certain legal concepts and to implement certain rules

Subsidiaries of Bausch Health Companies Inc.

Exhibit 21.1 Subsidiary Information As of February 19, 2025 Company Jurisdiction of Incorporation Bausch & Lomb Argentina S.R.L. Argentina Waicon Vision S.A. Argentina AcuFocus Australia Pty. Ltd Australia Bausch Health Australia Pty Limited Australia Bausch & Lomb (Australia) Pty Limited Australia Bausch & Lomb Australia Holdings Pty Limited Australia Solta Medical Australia Pty Limited Australia

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 19, 2025 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of inc

BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2024 RESULTS

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2024 RESULTS •Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceedin

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): November 1, 2024 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Co

Employment Agreement dated as of July 15, 2024 between Bausch Health Companies Inc. and Jean-Jacques Charhon.

Exhibit 10.1 BAUSCH HEALTH COMPANIES INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is hereby entered into as of July 15, 2024 (the “Effective Date”), by and between Bausch Health Companies Inc., a British Columbia corporation (“Bausch Health” or the “Company”), and Jean-Jacques Charhon, an individual (the “Executive”) (hereinafter collectively referred to as “the parties”).

Letter dated as of July 18, 2024, amending the offer letter to John Barresi, dated as of September 30, 2023.

Exhibit 10.2 July 18, 2024 John Barresi Senior Vice President, Controller and Chief Accounting Officer Dear John: I want to thank you for your hard work and dedication over the last ten months acting as Interim Chief Financial Officer. In recognition of your ongoing critical role to the Company’s continued success, I am pleased to award you a one-time Restricted Stock Unit Grant of $350,000. The a

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 30, 2024 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of inco

BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2024 RESULTS

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2024 RESULTS •Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1 •Third quarter consolidated revenues of $2.51 billion, up 12% on a R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 (State or other juris

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 (State or other jurisdiction of incorporation) (Commission file number) 2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8 (Address of Principal Executive Offices)

Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

Exhibit 1.01 Conflict Minerals Report For the Year ended December 31, 2023 Part I. Introduction This is the Conflict Minerals Report (“Report”) of Bausch Health Companies Inc. (“Bausch Health,” the “Company,” “we,” “our” or “us”) for calendar year 2023, prepared and submitted in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “1934 Act”). Please refer to Ru

BHC / Bausch Health Companies Inc. / MERUELO ALEX - BAUSCH HEALTH COMPANIES INC. Passive Investment

SC 13G 1 p24-2677sc13g.htm BAUSCH HEALTH COMPANIES INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bausch Health Companies Inc. (Name of Issuer) Common shares, no par value (Title of Class of Securities) 071734107 (CUSIP Number) June 26, 2024** (Date of Event Which Requires Filing of this Statement) Check the a

BHC / Bausch Health Companies Inc. / ICAHN CARL C - SC 13D/A Activist Investment

SC 13D/A 1 tm2421713d2sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.5)* Bausch Health Companies Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 071734107 (CUSIP Number) Jesse A. Lynn, Esq. Icahn Capital LP 16690 Collins Avenue Sunny Isles Beach, FL 33160 (305) 422-41

Amended and Restated Employee Matters Agreement dated as of July 31, 2024, by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation. †

Exhibit 10.2 AMENDED AND RESTATED EMPLOYEE MATTERS AGREEMENT by and between BAUSCH HEALTH COMPANIES INC. and BAUSCH + LOMB CORPORATION Dated as of July 31, 2024 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS Section 1.01. Certain Definitions 1 ARTICLE II GENERAL ALLOCATION OF LIABILITIES; INDEMNIFICATION Section 2.01. Allocation of Employee-Related Liabilities 8 Section 2.02. Indemnification 9 Secti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Compani

As filed with the Securities and Exchange Commission on August 1, 2024

As filed with the Securities and Exchange Commission on August 1, 2024 Registration No.

Bausch Health Companies Inc. 2014 Omnibus Incentive Plan, as amended and restated effective as of May 14, 2024.

Exhibit 99 Bausch Health Companies Inc. 2014 OMNIBUS INCENTIVE PLAN (As Amended and Restated, Effective as of May 14, 2024) 1. Purpose and Background The purposes of the Amended and Restated 2014 Omnibus Incentive Plan (as amended from time to time, the “Plan”) are to (i) align the long-term financial interests of employees, directors, consultants, agents and other service providers of the Company

Calculation of Filing Fee Tables

Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Bausch Health Companies Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common S

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 1, 2024 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorp

BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2024 RESULTS

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2024 RESULTS •Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basis •Consolidated GAAP Net Income Attributable to Bausc

Bausch Health Welcomes Two New Members to the Executive Leadership Team

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano [email protected] [email protected] (877) 281-6642 (toll free) (908) 569-3692 Bausch Health Welcomes Two New Members to the Executive Leadership Team LAVAL, Quebec, July 19, 2024 – Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced the appointment of two new members to its Executive Lea

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other jurisdiction of incorporation or orga

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 MAY 15, 2024 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorpor

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 2, 2024 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorpora

Offer Letter regarding Appointment of John Barresi as Interim Chief Financial Officer, dated as of September 26, 2023. ††

September 26, 2023 John Barresi Senior Vice President, Controller and Chief Accounting Officer Dear John: We are pleased to appoint you as interim Chief Financial Officer of Bausch Health Companies, Inc.

BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2024 RESULTS

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Kevin Wiggins [email protected] [email protected] (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2024 RESULTS •First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basis •Year-over-year revenue growth in all segments on both a Reported and Organic1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Compan

Second Amendment to Credit and Security Agreement, dated as of March 28, 2024, amending the Credit and Security Agreement, dated June 30, 2023, by and among Bausch Receivables Funding LP, as Borrower, Bausch Receivables Funding GP ULC, Bausch Health US, LLC, as the Master Servicer, GLAS USA LLC, as Administrative Agent, GLAS Americas LLC, as Collateral Agent, KKR Capital Markets LLC, as Left Lead Arranger, KKR Credit Advisors (US) LLC, as Structuring Advisor, and the Lenders from time to time party thereto.

EXHIBIT 10.1 SECOND AMENDMENT TO CREDIT AND SECURITY AGREEMENT This Second Amendment to Credit and Security Agreement (this “Amendment”), dated as of March 28, 2024 amends the Credit and Security Agreement (as amended to date, the “Credit and Security Agreement”), dated as of June 30, 2023, by and among Bausch Receivables Funding LP, a limited partnership organized under the laws of the Province o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement  ☐ Definitive Additional Materials  ☐ Soliciting Material Pursuant to § 240.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials  ☐ Soliciting Material Pursuant to § 240.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Companies I

Subsidiaries of Bausch Health Companies Inc.

Exhibit 21.1 Subsidiary Information As of February 22, 2024 Company Jurisdiction of Incorporation Bausch & Lomb Argentina S.R.L. Argentina Waicon Vision S.A. Argentina AcuFocus Australia Pty. Ltd Australia Bausch Health Australia Pty Limited Australia Bausch & Lomb (Australia) Pty Limited Australia Bausch & Lomb Australia Holdings Pty Limited Australia Solta Medical Australia Pty Limited Australia

First Amendment to Credit and Security Agreement, dated as of August 9, 2023, amending the Credit and Security Agreement, dated June 30, 2023, by and among Bausch Receivables Funding LP, as Borrower, Bausch Receivables Funding GP ULC, Bausch Health US, LLC, as the Master Servicer, GLAS USA LLC, as Administrative Agent, GLAS Americas LLC, as Collateral Agent, KKR Capital Markets LLC, as Left Lead Arranger, KKR Credit Advisors (US) LLC, as Structuring Advisor, and the Lenders from time to time party thereto.*

Exhibit 10.55 EXECUTION VERSION FIRST AMENDMENT TO CREDIT AND SECURITY AGREEMENT This First Amendment to Credit and Security Agreement (this "Amendment"), dated as of August 9, 2023 amends the Credit and Security Agreement (as amended to date, the "Credit and Security Agreement"), dated as of June 30, 2023, by and among Bausch Receivables Funding LP, a limited partnership organized under the laws

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 22, 2024 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of inc

Bausch Health Companies Inc. Compensation Recoupment Policy dated as of July 20, 2023*†

Exhibit 97 BAUSCH HEALTH COMPANIES INC. COMPENSATION RECOUPMENT POLICY This Bausch Health Companies Inc. Compensation Recoupment Policy (the “Policy”) has been adopted by the Talent and Compensation Committee of the Board of Directors (the “Board”) of Bausch Health Companies Inc. (the “Company”) on July 20, 2023. This Policy provides for the recoupment of certain executive compensation in the even

BAUSCH HEALTH ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2023 RESULTS

Exhibit 99.1 Investor Contacts: Media Contact: Solebury Strategic Communications Kevin Wiggins [email protected] [email protected] (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2023 RESULTS •Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic1 basis •Full-Year revenues of $8.76 billi

BHC / Bausch Health Companies Inc. / GOLDENTREE ASSET MANAGEMENT LP Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Bausch Health Companies Inc. (Name of Issuer) Common Shares (Title of Cla

BHC / Bausch Health Companies Inc. / ICAHN CARL C - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.4)* Bausch Health Companies Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 071734107 (CUSIP Number) Jesse A. Lynn, Esq. Icahn Capital LP 16690 Collins Avenue Sunny Isles Beach, FL 33160 (305) 422-4100 (Name, Address and Telephone Number of

Bausch Health Announces Board Refreshment

Exhibit 99.1 Investor Contact: Media Contacts: Kevin Wiggins [email protected] [email protected] (908) 541-2102 (908) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces Board Refreshment LAVAL, Quebec, Feb. 1, 2024 – Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced, as part of its ongoing commitment to board refreshment and board diversity, its nomina

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 JANUARY 29, 2024 Date of report (Date of earliest event reported) Bausch Health Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 JANUARY 29, 2024 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of inco

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): September 29, 2023 Bausch Health Companie

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): September 29, 2023 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporat

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

EX-99.3 Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On June 30, 2023, a wholly owned subsidiary of Bausch + Lomb Corporation (“Bausch + Lomb” or “B+L”) (a subsidiary of Bausch Health Companies Inc. (the “Company”)), Bausch + Lomb Ireland Limited (“Buyer”), entered into a Stock and Asset Purchase Agreement (as amended, modified or supplemented, the “Acquisition Agreeme

BAUSCH HEALTH ANNOUNCES THIRD-QUARTER 2023 RESULTS

Exhibit 99.1 Investor Contacts: Media Contact: Lisa Wilson Kevin Wiggins [email protected] [email protected] (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES THIRD-QUARTER 2023 RESULTS •Revenue of $2.24 billion, up 9% on both a Reported and Organic1 basis •Year-over-year revenue growth in all segments on both a Reported and Organic Basis •GAAP Net Loss At

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 2, 2023 Date of report (Date of earliest event reported) Bausch Health Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 2, 2023 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Co

Indenture, dated as of September 29, 2023, by and among Bausch + Lomb Corporation, the guarantors party thereto and Citibank, N.A., acting through its agency and trust division, as trustee, and as notes collateral agent thereto, originally filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on September 29, 2023 and incorporated by reference herein.

Exhibit 4.1 Execution Version BAUSCH + LOMB CORPORATION $1,400,000,000 8.375% SENIOR SECURED NOTES DUE 2028 INDENTURE DATED AS OF SEPTEMBER 29, 2023 CITIBANK, N.A., AS TRUSTEE, REGISTRAR, TRANSFER AGENT, PAYING AGENT AND NOTES COLLATERAL AGENT TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.1 Definitions 1 Section 1.2 Other Definitions 51 Section 1.3 Rules of

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): September 29, 2023 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction o

Bausch Health’s Bausch + Lomb Announces Completion of the Acquisition of XIIDRA®

Exhibit 99.1 Investor Contact: Mark Maico [email protected] (908) 541-2102 (877) 281-6642 (toll free) Media Contact: Kevin Wiggins [email protected] (908) 541-3785 Bausch Health’s Bausch + Lomb Announces Completion of the Acquisition of XIIDRA® LAVAL, Quebec, September 29, 2023 – Bausch + Lomb Corporation (“Bausch + Lomb”) (NYSE/TSX: BLCO), a subsidiary of Bausch Health C

Credit Agreement, dated as of May 10, 2022, as amended by the First Incremental Amendment, dated as of September 29, 2023, by and among Bausch + Lomb Corporation, certain subsidiaries of Bausch + Lomb Corporation as subsidiary guarantors, the lenders party thereto, Citibank, N.A., as collateral agent thereto, Goldman Sachs Bank USA, as term facility administrative agent thereto and JPMorgan Chase Bank, N.A., as first incremental term facility administrative agent thereto, originally filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 29, 2023, which is incorporated by reference herein.

Exhibit 10.1 Execution Version FIRST INCREMENTAL AMENDMENT (this “Amendment”), dated as of September 29, 2023, among Bausch + Lomb Corporation, a corporation incorporated under the Canada Business Corporations Act (the “Borrower”), certain subsidiaries of the Borrower, as Subsidiary Guarantors, the New Term Lenders party hereto, Goldman Sachs Bank USA (“Goldman Sachs”), in its capacity as administ

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other jurisdiction

BAUSCH HEALTH ANNOUNCES CFO TRANSITION PLAN

Exhibit 99.1 Investor Contacts: Media Contact: John O’Connor Kevin Wiggins [email protected] [email protected] (908) 541-2973 (908) 927-1198 Mark Maico [email protected] (908) 541-2102 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES CFO TRANSITION PLAN LAVAL, Quebec, Sept. 18, 2023 - Bausch Health Companies Inc. (NYSE/TSX: BHC) (“BHC” or the “Company”) today announce

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): September 18, 2023 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporatio

Other Events

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): September 14, 2023 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporatio

Bausch Health’s Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®

EX-99.1 Exhibit 99.1 Investor Contacts: John O’Connor [email protected] (908) 541-2973 Media Contact: Kevin Wiggins [email protected] (908) 541-3785 Mark Maico [email protected] (908) 541-2102 (877) 281-6642 (toll free) Bausch Health’s Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA® LAVAL, Quebec, September 11, 2023 – Bausch + Lomb Corpora

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): September 11, 2023 Bausch Health Companies

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): September 11, 2023 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporatio

Independent Auditors’ Report

Exhibit 99.1 Independent Auditors’ Report To Management of Novartis Pharma AG Report on the Audit of the Abbreviated Financial Statements Opinion We have audited the abbreviated financial statements related to the worldwide rights to Xiidra®, AcuStream, SAF312, and OJL332 (collectively, “the Assets”) of Novartis Group (‘Novartis’), which comprise abbreviated statements of assets acquired and liabi

Regulation FD Disclosure, Financial Statements and Exhibits

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): September 6, 2023 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation

Xiidra®, AcuStream, SAF312, OJL332 Assets of Novartis Group Interim Abbreviated Financial Statements (in US Dollar thousand) For the six months ended June 30, 2023 and June 30, 2022

Exhibit 99.2 Xiidra®, AcuStream, SAF312, OJL332 Assets of Novartis Group Interim Abbreviated Financial Statements (Unaudited) (in US Dollar thousand) For the six months ended June 30, 2023 and June 30, 2022 Xiidra®, AcuStream, SAF312, OJL332 Assets of Novartis Group Interim Abbreviated Financial Statements (Unaudited) Statements of Assets Acquired and Liabilities Assumed Note As of June 30, 2023 (

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On June 30, 2023, a wholly owned subsidiary of Bausch + Lomb Corporation (the “Company,” “Bausch + Lomb” or “B+L”), Bausch + Lomb Ireland Limited (“Buyer”), entered into a Stock and Asset Purchase Agreement (the “Acquisition Agreement”) with Novartis Pharma AG, Novartis Finance Corporation (together with Novartis Pharma AG,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Compani

As filed with the Securities and Exchange Commission on August 3, 2023

As filed with the Securities and Exchange Commission on August 3, 2023 Registration No.

BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2023 RESULTS, OTHER KEY UPDATES FROM THE QUARTER, AND RAISES FULL-YEAR 2023 REVENUE OUTLOOK

Exhibit 99.1 Investor Contacts: Media Contact: John O'Connor Kevin Wiggins [email protected] [email protected] (908) 541-2973 (908) 541-3785 Mark Maico [email protected] (908) 541-2102 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2023 RESULTS, OTHER KEY UPDATES FROM THE QUARTER, AND RAISES FULL-YEAR 2023 REVENUE OUTLOOK •Favorable Motion Ruling in X

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 3, 2023 Date of report (Date of earliest event reported) Bausch Health Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 3, 2023 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorp

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Table Form S-8 Registration Statement Under the Securities Act of 1933 (Form Type) Bausch Health Companies Inc.

Bausch Health Companies Inc. 2014 Omnibus Incentive Plan, as amended and restated effective as of May 16, 2023.

Exhibit 99 Bausch Health Companies Inc. 2014 OMNIBUS INCENTIVE PLAN (As Amended and Restated, Effective as of May 16, 2023) 1. Purpose and Background The purposes of the Amended and Restated 2014 Omnibus Incentive Plan (as amended from time to time, the “Plan”) are to (i) align the long-term financial interests of employees, directors, consultants, agents and other service providers of the Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 (State or other juris

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 (State or other jurisdiction of incorporation) (Commission file number) 2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8 (Address of Principal Executive Offices)

Conflict Minerals Report For the Year ended December 31, 2022

EX-1.01 Exhibit 1.01 Conflict Minerals Report For the Year ended December 31, 2022 Part I. Introduction This is the Conflict Minerals Report (“Report”) of Bausch Health Companies Inc. (“Bausch Health,” the “Company,” “we,” “our” or “us”) for calendar year 2022, prepared and submitted in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “1934 Act”). Please ref

Credit and Security Agreement, dated June 30, 2023, by and among Bausch Receivables Funding LP, as Borrower, Bausch Receivables Funding GP ULC, Bausch Health US, LLC, as the Master Servicer, GLAS USA LLC, as Administrative Agent, GLAS Americas LLC, as Collateral Agent, KKR Capital Markets LLC, as Left Lead Arranger, KKR Credit Advisors (US) LLC, as Structuring Advisor, and the Lenders from time to time party thereto, originally filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 7, 2023, which is incorporated by reference herein. ††

EX-10.1 Exhibit 10.1 EXECUTION VERSION CREDIT AND SECURITY AGREEMENT DATED AS OF JUNE 30, 2023 AMONG BAUSCH RECEIVABLES FUNDING LP, AS BORROWER, BAUSCH RECEIVABLES FUNDING GP ULC, BAUSCH HEALTH US, LLC, AS THE MASTER SERVICER, THE LENDERS FROM TIME TO TIME PARTY HERETO, GLAS USA LLC, AS ADMINISTRATIVE AGENT, GLAS AMERICAS LLC, AS COLLATERAL AGENT KKR CAPITAL MARKETS LLC, AS LEFT LEAD ARRANGER AND

Bausch Health Enters Into $600 Million Financing Facility With KKR

EX-99.1 Exhibit 99.1 Investor Contact: Media Contact: Mark Maico Kevin Wiggins [email protected] [email protected] (877) 281-6642 (toll free) (908) 541-3785 Julia Kosygina [email protected] (212) 750-8300 Bausch Health Enters Into $600 Million Financing Facility With KKR LAVAL, Quebec, July 7, 2023 – Bausch Health Companies Inc. (NYSE/TSX: BHC) and KKR today announced that Ba

Stock and Asset Purchase Agreement by and among Bausch + Lomb Ireland Limited, Novartis Pharma AG and Novartis Finance Corporation and, for the limited purposes set forth therein, Bausch + Lomb Corporation, dated as June 30, 2023, originally filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on July 7, 2023, which is incorporated by reference herein. ††

EX-2.1 Exhibit 2.1 STOCK AND ASSET PURCHASE AGREEMENT by and among Novartis Pharma AG, Novartis Finance Corporation, Bausch + Lomb Ireland Limited and Bausch + Lomb Corporation, solely for the purposes of Article 1 and Section 10.17 Dated as of June 30, 2023 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.1 Certain Defined Terms 2 1.2 Construction 24 ARTICLE 2 PURCHASE AND SALE; LIABILITIES 25 2.1 Pur

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 30, 2023 Bausch Health Companies Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 30, 2023 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation or

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 30, 2023 Bausch Health Companies Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 30, 2023 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation or

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 30, 2023 Bausch Health Companies Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 30, 2023 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation or

Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA®

Exhibit 99.1 Investor Contact: Media Contact: Mark Maico Kevin Wiggins [email protected] [email protected] (877) 281-6642 (toll free) (908) 541-3785 Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA® LAVAL, Quebec, June 30, 2023 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), announced that it has entered

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 MAY 17, 2023 Date of report (Date of earliest event reported) Bausch Health Compani

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 MAY 17, 2023 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorpor

BAUSCH HEALTH ANNOUNCES FIRST-QUARTER 2023 RESULTS

Exhibit 99.1 Investor Contact: Media Contact: Mark Maico Kevin Wiggins [email protected] [email protected] (908) 541-2102 (908) 541-3785 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES FIRST-QUARTER 2023 RESULTS •First-Quarter revenues of $1.94 billion, up 1% reported and 4% organic1 •Solid revenue growth across core products, led by Xifaxan with 7% reported growth •Mi

Form of PSU Award Agreement, originally filed as Exhibit 10.1 to the Company’s Current Report on Form 10-Q filed on May 4, 2023, which is incorporated by reference herein. †

Bausch Health Companies Inc. Form of Share Unit Grant Agreement (Performance Vesting) (Performance Restricted Share Units) (2014 Omnibus Incentive Plan, as amended and restated, effective as of June 21, 2022) Bausch Health Companies Inc. (the “Company”), pursuant to Section 7(c) of the Company’s 2014 Omnibus Incentive Plan, as amended and restated, effective as of June 21, 2022 (the “Plan”), hereb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 4, 2023 Date of report (Date of earliest event reported) Bausch Health Companie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 4, 2023 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement  ☐ Definitive Additional Materials  ☐ Soliciting Material Pursuant to § 240.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement  ☒ Definitive Additional Materials  ☐ Soliciting Material Pursuant to § 240.

Bausch Health Announces Changes to its Board of Directors

Exhibit 99.1 Investor Contact: Media Contact: Kevin Wiggins [email protected] [email protected] (514) 856-3855 (908) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces Changes to its Board of Directors LAVAL, Quebec, March 1, 2023 – Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Richard De Schutter and Dr. Argeris Karabelas are retiring from th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 MARCH 1, 2023 Date of report (Date of earliest event reported) Bausch Health Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 MARCH 1, 2023 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 23, 2023 Date of report (Date of earliest event reported) Bausch Health Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 23, 2023 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Companies I

Subsidiaries of Bausch Health Companies Inc.

Exhibit 21.1 Subsidiary Information As of February 23, 2023 Company Jurisdiction of Incorporation Doing Business As Bausch & Lomb Argentina S.R.L. Argentina Bausch & Lomb Argentina S.R.L. Waicon Vision S.A. Argentina Waicon Vision S.A. Bausch & Lomb (Australia) Pty Limited Australia Bausch & Lomb (Australia) Pty Limited Bausch Health Australia Pty Limited Australia Bausch Health Australia Pty Limi

BAUSCH HEALTH ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2022 RESULTS

EX-99.1 2 ex991-q4x2022.htm EX-99.1 Exhibit 99.1 Investor Contact: Media Contact: Mark Maico Kevin Wiggins [email protected] [email protected] (908) 541-2102 (908) 541-3785 BAUSCH HEALTH ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2022 RESULTS •Fourth-Quarter revenues of $2.2 billion, flat reported, up 4% organic1 •Full-Year revenues of $8.1 billion, down 4% reported, up 2% or

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): February 15, 2023 Bausch Health Companies I

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): February 15, 2023 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation

BHC / BauschHealth?Companies?Inc. / NOMURA HOLDINGS INC - SC 13G/A Passive Investment

SC 13G/A 1 brhc10047770sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bausch Health Companies Inc. (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 071734107 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check t

BLCO / Bausch + Lomb Corp / Valeant Pharmaceuticals International, Inc. - SC 13G Passive Investment

SC 13G 1 d459284dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bausch + Lomb Corporation (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 071705107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriat

Joint Filing Agreement (previously filed).

EX-99 2 d463324dex99.htm EX-99 CUSIP No. 071734107 Schedule 13G Page 9 of 9 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, a

BHC / BauschHealth?Companies?Inc. / GOLDENTREE ASSET MANAGEMENT LP - SC 13G Passive Investment

SC 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Bausch Health Companies Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 071734107 (CUSIP

Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Documents

EX-99.1 Exhibit 99.1 Investor Contact: Media Contacts: Christina Cheng Kevin Wiggins [email protected] [email protected] (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Documents LAVAL, Quebec, Nov. 29, 2022 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 29, 2022 Bausch Health C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 29, 2022 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other jurisdiction of inc

Fifteenth Supplemental Indenture, dated as of September 28, 2022, by and among Bausch Health Companies Inc. and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of May 23, 2019 relating to the Company’s 7.250% Senior Notes due 2029, originally filed as 10.8 to the Company’s Current Report on Form 10-Q filed on November 3, 2022, which is incorporated by reference herein.

Exhibit 10.5 FIFTEENTH SUPPLEMENTAL INDENTURE This Fifteenth Supplemental Indenture, dated as of September 28, 2022 (this ?Supplemental Indenture?), by and between Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia (the ?Company?), and The Bank of New York Mellon, as trustee (?Trustee?) under the Indenture referred to below. WITNESSETH: WHEREAS

Sixteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Americas, Inc. and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of March 26, 2018 relating to the BHA’s 9.250% Senior Notes due 2026, originally filed as Exhibit 10.4 to the Company’s Current Report on Form 10-Q filed on November 3, 2022, which is incorporated by reference herein

Exhibit 10.4 SIXTEENTH SUPPLEMENTAL INDENTURE This Sixteenth Supplemental Indenture, dated as of September 14, 2022 (this ?Supplemental Indenture?), by and between Bausch Health Americas, Inc., a Delaware corporation (the ?Company?), and The Bank of New York Mellon, as trustee (?Trustee?) under the Indenture referred to below. WITNESSETH: WHEREAS, each of the Company and the guarantors party there

Sixteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Americas, Inc. (“BHA”) and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of June 1, 2018 relating to the BHA’s 8.500% Senior Notes due 2027, originally filed as 10.5 to the Company’s Current Report on Form 10-Q filed on November 3, 2022, which is incorporated by reference herein.

Exhibit 10.8 SIXTEENTH SUPPLEMENTAL INDENTURE This Sixteenth Supplemental Indenture, dated as of September 14, 2022 (this ?Supplemental Indenture?), by and between Bausch Health Americas, Inc., a Delaware corporation (the ?Company?), and The Bank of New York Mellon, as trustee (?Trustee?) under the Indenture referred to below. WITNESSETH: WHEREAS, each of the Company and the guarantors party there

Fourteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Companies Inc. and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of December 30, 2019 relating to the Company’s 5.000% Senior Notes due 2028, originally filed as 10.7 to the Company’s Current Report on Form 10-Q filed on November 3, 2022, which is incorporated by reference herein.

Exhibit 10.7 FOURTEENTH SUPPLEMENTAL INDENTURE This Fourteenth Supplemental Indenture, dated as of September 14, 2022 (this ?Supplemental Indenture?), by and between Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia (the ?Company?), and The Bank of New York Mellon, as trustee (?Trustee?) under the Indenture referred to below. WITNESSETH: WHERE

BAUSCH HEALTH ANNOUNCES THIRD-QUARTER 2022 RESULTS

Exhibit 99.1 Investor Contact: Media Contact: Christina Cheng Kevin Wiggins [email protected] [email protected] (514) 856-3855 (908) 541-3785 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES THIRD-QUARTER 2022 RESULTS ?Revenues of $2.046 billion, down 3% reported, up 2% organic basis ?Third quarter sales improved sequentially, notably Salix, International, and Solta ?Su

Fourteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Companies Inc. and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of May 23, 2019 relating to the Company’s 7.000% Senior Notes due 2028, originally filed as 10.6 to the Company’s Current Report on Form 10-Q filed on November 3, 2022, which is incorporated by reference herein.

Exhibit 10.6 FOURTEENTH SUPPLEMENTAL INDENTURE This Fourteenth Supplemental Indenture, dated as of September 14, 2022 (this ?Supplemental Indenture?), by and between Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia (the ?Company?), and The Bank of New York Mellon, as trustee (?Trustee?) under the Indenture referred to below. WITNESSETH: WHERE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Co

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 3, 2022 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of inco

Indenture, dated as of September 30, 2022, by and among 1375209 B.C. Ltd., The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, as notes collateral agent, governing the 9.00% Senior Secured Notes due 2028, originally filed as Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on October 4, 2022, which is incorporated by reference herein.

Exhibit 4.3 1375209 B.C. LTD. $998,937,000 9.000% SENIOR SECURED NOTES DUE 2028 INDENTURE DATED AS OF SEPTEMBER 30, 2022 THE BANK OF NEW YORK MELLON, AS TRUSTEE, REGISTRAR, PAYING AGENT AND NOTES COLLATERAL AGENT TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.1 Definitions 1 Section 1.2 Other Definitions 16 Section 1.3 Rules of Construction 17 ARTICLE 2 THE S

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 4, 2022 (September 30, 2022) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other

Indenture, dated as of September 30, 2022, by and among Bausch Health Companies Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee, and the notes collateral agents party thereto, governing the 14.00% Senior Secured Notes due 2030, originally filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on October 4, 2022, which is incorporated by reference herein.

EX-4.2 3 d397743dex42.htm EX-4.2 Exhibit 4.2 BAUSCH HEALTH COMPANIES INC. $351,533,000 14.000% SECOND LIEN SECURED NOTES DUE 2030 INDENTURE DATED AS OF SEPTEMBER 30, 2022 THE BANK OF NEW YORK MELLON, AS TRUSTEE, REGISTRAR AND PAYING AGENT AND THE NOTES COLLATERAL AGENTS PARTY HERETO TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.1 Definitions 1 Section 1.2 Ot

Indenture, dated as of September 30, 2022, by and among Bausch Health Companies Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee, and the notes collateral agents party thereto, governing the 11.00% Senior Secured Notes due 2028, originally filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on October 4, 2022, which is incorporated by reference herein

Exhibit 4.1 BAUSCH HEALTH COMPANIES INC. $1,774,067,000 11.00% SENIOR SECURED NOTES DUE 2028 INDENTURE DATED AS OF SEPTEMBER 30, 2022 THE BANK OF NEW YORK MELLON, AS TRUSTEE, REGISTRAR AND PAYING AGENT AND THE NOTES COLLATERAL AGENTS PARTY HERETO TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.1 Definitions 1 Section 1.2 Other Definitions 31 Section 1.3 Rules

Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations

Investor Contact: Media Contacts: Christina Cheng Kevin Wiggins [email protected] [email protected] (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations LAVAL, Quebec ? Sept. 28, 2022 ? Bausch Health Companies Inc. (NYSE/TSX: BHC) (the ?Company?) announced today the final

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 September 28, 2022 Date of report (Date of the earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or Other Jurisdiction o

Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations

Investor Contact: Media Contacts: Christina Cheng Kevin Wiggins [email protected] [email protected] (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations LAVAL, Quebec ? Sept. 14, 2022 ? Bausch Health Companies Inc. (NYSE/TSX: BHC) (the ?Company?) announced today the resu

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 September 14, 2022 Date of report (Date of the earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or Other Jurisdiction o

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 September 9, 2022 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bau

Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes

Exhibit 99.1 Investor Contact: Media Contacts: Christina Cheng Kevin Wiggins [email protected] [email protected] (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes LAVAL, Quebec ? Aug. 30, 2022 ?

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 31, 2022 (August 30, 2022) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other jur

Bausch Health Continuing Process Toward Separating Bausch + Lomb

Exhibit 99.1 Investor Contact: Media Contacts: Christina Cheng Kevin Wiggins [email protected] [email protected] (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Continuing Process Toward Separating Bausch + Lomb LAVAL, Quebec, Aug. 22, 2022 ? Bausch Health Companies Inc. (NYSE/TSX: BHC) (?Bausch Health? or the ?Company?) has transferred common share

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 22, 2022 (August 19, 2022) Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other juri

BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS

Exhibit 99.1 Investor Contact: Media Contact: Christina Cheng Kevin Wiggins [email protected] [email protected] (514) 856-3855 (908) 541-3785 (877) 281-6642 (toll free) BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS ?Revenues of $1.967 billion ?Company to appeal anticipated court decision and vigorously defend XIFAXAN intellectual property ?Balance sheet continues to

Employment Agreement, dated as of May 28, 2020, by and between Bausch Health Companies Inc. and Robert Spurr. ††

Exhibit 10.9 BAUSCH HEALTH COMPANIES INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is hereby entered into as of May 28, 2020 (the “Effective Date”), retroactive to May 27, 2020, by and between Bausch Health Companies Inc., a Canadian corporation (the “Company”), and Robert Spurr, an individual (the “Executive”) (hereinafter collectively referred to as “the parties”). Where

Bausch Health Companies Inc. Amended and Restated 2014 Omnibus Incentive Plan, amended and restated effective as of June 21, 2022

Exhibit 99.1 Bausch Health Companies Inc. 2014 OMNIBUS INCENTIVE PLAN (As Amended and Restated, Effective as of June 21, 2022) 1. Purpose and Background The purposes of the Amended and Restated 2014 Omnibus Incentive Plan (as amended from time to time, the ?Plan?) are to (i) align the long-term financial interests of employees, directors, consultants, agents and other service providers of the Comp

As filed with the Securities and Exchange Commission on August 9, 2022

As filed with the Securities and Exchange Commission on August 9, 2022 Registration No.

Employment Agreement, dated as of October 20, 2021, by and between Bausch Health Companies Inc. and Tom Vadaketh, originally filed as 10.7 to the Company’s Current Report on Form 10-Q filed on August 9, 2022, which is incorporated by reference herein. ††

Exhibit 10.7 BAUSCH HEALTH COMPANIES INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is hereby entered into as of October 20, 2021, by and between Bausch Health Companies Inc., a British Columbia corporation (?Bausch Health? or the ?Company?), and Tom Vadaketh, an individual (the ?Executive?) (hereinafter collectively referred to as ?the parties?). Where the context requires,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 9, 2022 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorp

Calculation of filing fee table

Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BAUSCH HEALTH COMPANIES INC. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rat

Employment Agreement, dated as of December 3, 2021, by and between Bausch Health Companies Inc. and Seana Carson, originally filed as 10.8 to the Company’s Current Report on Form 10-Q filed on August 9, 2022, which is incorporated by reference herein. ††

Exhibit 10.8 BAUSCH HEALTH COMPANIES INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is hereby entered into as of December 3, 2021, by and between Bausch Health Companies Inc., a company incorporated in the Province of British Columbia, Canada (together with any successor thereto, ?Bausch Health? or the ?Company?), and Seana Carson, an individual (the ?Executive?) (hereinafte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Compani

Amendment to Employment Agreement dated September 1, 2021 by and between Bausch Health Companies Inc. and Robert Spurr. ††

Exhibit 10.10 BAUSCH HEALTH COMPANIES INC. AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?) is made as of September 1, 2021 by and between Bausch Health Companies Inc., a Canadian corporation (the ?Company?), and Robert Spurr, an individual (the ?Executive?). Where the context requires, references to the Company in the Agreement (as defined below) and thi

Separation Agreement, dated as of June 1, 2022, by and between Bausch Health Companies Inc. and Robert Spurr. ††

Exhibit 10.11 BAUSCH HEALTH COMPANIES INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is hereby entered into as of May 28, 2020 (the “Effective Date”), retroactive to May 27, 2020, by and between Bausch Health Companies Inc., a Canadian corporation (the “Company”), and Robert Spurr, an individual (the “Executive”) (hereinafter collectively referred to as “the parties”). Where

Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation -- Company to Appeal Expected Court Decision on Certain XIFAXAN® Patents –

Investor Contact: Media Contacts: Christina Cheng Kevin Wiggins [email protected] [email protected] (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation - Company to Appeal Expected Court Decision on Certain XIFAXAN® Patents – LAVAL, Quebec, July 28, 2022 – Bausch Health Companies Inc. (N

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 29, 2022 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorpo

Regulation FD Disclosure

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): July 20, 2022 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation or

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 21, 2022 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation or

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 21, 2022 Date of Report (Date of the earliest event reported) Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Inco

Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors

Exhibit 99.1 Investor Contact: Christina Cheng [email protected] (514) 856-3855 (877) 281-6642 (toll free) Media Contact: Lainie Keller [email protected] (908) 927-1198 Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors LAVAL, Quebec, June 23, 2022 ? Bausch Health Companies Inc. (NYSE/TSX: BHC) (?Bausch Health? or the ?

Agenda 2 3 4 1 Call to order Procedural matters Voting items and results Management presentation 5 Q&A

2021 Annual Meeting of Shareholders June 21, 2022 Exhibit 99.1 Agenda 2 3 4 1 Call to order Procedural matters Voting items and results Management presentation 5 Q&A Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applicable securities laws, including, but not limited to, statements regarding the Company?s future prospects and performance, the

BAUSCH HEALTH ISSUES FORM 8-K FOR 2022 ANNUAL MEETING OF SHAREHOLDERS PRESENTATION

Exhibit 99.2 Investor Contact: Media Contact: Christina Cheng Lainie Keller [email protected] [email protected] (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH ISSUES FORM 8-K FOR 2022 ANNUAL MEETING OF SHAREHOLDERS PRESENTATION LAVAL, Quebec, June 21, 2022 ? Bausch Health Companies Inc. (NYSE/TSX: BHC) (?Bausch Health? or the ?Company?) today ann

Regulation FD Disclosure, Financial Statements and Exhibits

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): June 21, 2022 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other jurisdiction of incorporation or organ

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

Exhibit 1.01 Conflict Minerals Report For the Year ended December 31, 2021 Part I. Introduction This is the Conflict Minerals Report (?Report?) of Bausch Health Companies Inc. (?Bausch Health? or the ?Company?) for calendar year 2021, prepared and submitted in accordance with Rule 13p-1 (?Rule 13p-1?) under the Securities Exchange Act of 1934 (the ?1934 Act?). Please refer to Rule 13p-1, Form SD a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BAUSCH HEALTH COMPANIES INC. (Exact name of the registrant as specified in its charter) Bausch Health Companies Inc. (Exact name of registra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BAUSCH HEALTH COMPANIES INC. (Exact name of the registrant as specified in its charter) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorporation or organization) (Commiss

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or other jurisdiction of incorporation or organ

Explanatory Note

Exhibit 99.2 Explanatory Note On August 3, 2021, the Company announced its intentions to conduct an initial public offering (“IPO”) of its aesthetic medical device business, Global Solta (“Solta”) (the “Solta IPO”). See Note 2, “SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Use of Estimates - Separation of the Bausch + Lomb Eye-Health Business and Initial Public Offering of Solta Med

Explanatory Note

Exhibit 99.1 Explanatory Note On August 3, 2021, the Company announced its intentions to conduct an initial public offering (?IPO?) of its aesthetic medical device business, Global Solta (?Solta?) (the ?Solta IPO?). See See ?Separation of the Bausch + Lomb Eye-Health Business and the Solta Medical Business? below for further details regarding the Solta IPO. In connection with the planned separatio

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 10, 2022 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorpor

Second Amendment to the Fourth Amended & Restated Credit and Guaranty Agreement, dated as of May 10, 2022, among Bausch Health Companies Inc., Bausch Health Americas, Inc., certain other subsidiaries of the Company as subsidiary guarantors, each of the financial institutions named therein as lenders and issuing banks and Barclays Bank PLC, as Administrative Agent, originally filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 10, 2022, which is incorporated by reference herein.

Exhibit 10.1 Execution Version SECOND AMENDMENT TO THE FOURTH AMENDED & RESTATED CREDIT AND GUARANTY AGREEMENT SECOND AMENDMENT, dated as of May 10, 2022 (this ?Agreement?), by and among BAUSCH HEALTH COMPANIES INC. (f/k/a Valeant Pharmaceuticals International, Inc.), a corporation continued under the laws of the Province of British Columbia (the ?Parent?), BAUSCH HEALTH AMERICAS, INC. (f/k/a Vale

BAUSCH HEALTH COMPANIES INC. ANNOUNCES FIRST-QUARTER 2022 RESULTS

Exhibit 99.1 Investor Contact: Media Contact: Christina Cheng Lainie Keller [email protected] [email protected] (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES FIRST-QUARTER 2022 RESULTS ?First-Quarter 2022 Financial Results ?Revenues of $1.918 Billion ?GAAP Net Loss of $69 Million ?Adjusted EBITDA (non-GAAP)1 of $732 Mill

Form of RSU Grant Agreement, originally filed as Exhibit 10.13 to the Company’s Current Report on Form 10-Q filed on May 10, 2022, which is incorporated by reference herein. ††

EX-10.13 2 exhibit1013formofrsugranta.htm EX-10.13 Exhibit 10.13 Bausch Health Companies Inc. Form of Restricted Share Unit Award Agreement (Restricted Share Units) (2014 Omnibus Incentive Plan, as amended and restated, effective as of April 28, 2020) Bausch Health Companies Inc. (the “Company”), pursuant to Section 7(c)(v) of the Company’s 2014 Omnibus Incentive Plan, as amended and restated, eff

BAUSCH HEALTH AND BAUSCH + LOMB CORPORATION ANNOUNCE CLOSING OF INITIAL PUBLIC OFFERING OF BAUSCH + LOMB AND RELATED DEBT TRANSACTIONS

EX-99.1 4 d298928dex991.htm EX-99.1 Exhibit 99.1 Investor Contact: Media Contact: Christina Cheng Lainie Keller [email protected] [email protected] (908) 927-1198 Arthur Shannon [email protected] (514) 856-3855 (877) 281-6642 (toll free) BAUSCH HEALTH AND BAUSCH + LOMB CORPORATION ANNOUNCE CLOSING OF INITIAL PUBLIC OFFERING OF BAUSCH + LOMB AND RELATED DEB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Compan

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2022 (May 5, 2022) Date of Report (Date of the earliest event reported) Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdi

Form of Option Grant Agreement, originally filed as Exhibit 10.14 to the Company’s Current Report on Form 10-Q filed on May 10, 2022, which is incorporated by reference herein. ††

Exhibit 10.14 BAUSCH HEALTH COMPANIES INC. FORM OF STOCK OPTION GRANT AGREEMENT (NONSTATUTORY STOCK OPTION) (2014 Omnibus Incentive Plan, as amended and restated, effective as of April 28, 2020) Bausch Health Companies Inc. (the ?Company?), pursuant to Section 7(a) of the Company?s 2014 Omnibus Incentive Plan, as amended and restated, effective as of April 28, 2020 (the ?Plan?), hereby grants to y

Credit Agreement, dated as of May 10, 2022, among Bausch + Lomb Corporation, certain subsidiaries of the Company as subsidiary guarantors, each of the financial institutions named therein as lenders and issuing banks, Citibank, N.A., as Revolving Facility Administrative Agent and Goldman Sachs Bank USA, as Term Facility Administrative Agent, originally filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on May 10, 2022, which is incorporated by reference herein.

Exhibit 10.2 EXECUTION VERSION CREDIT AND GUARANTY AGREEMENT dated as of May 10, 2022 among BAUSCH + LOMB CORPORATION, as the Borrower, CERTAIN SUBSIDIARIES OF BAUSCH + LOMB CORPORATION, as Subsidiary Guarantors, THE FINANCIAL INSTITUTIONS PARTY HERETO, as Lenders and Issuing Banks, CITIBANK, N.A., as Revolving Facility Administrative Agent and Swingline Lender, GOLDMAN SACHS BANK USA, as Term Fac

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 10, 2022 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A 1 d296110ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A 1 d766347ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as

AMENDMENT TO MASTER SEPARATION AGREEMENT

Exhibit 99.2 Executive Version AMENDMENT TO MASTER SEPARATION AGREEMENT This AMENDMENT NO. 1 TO MASTER SEPARATION AGREEMENT, dated as of April 28, 2022 (this ?Amendment?), is by and between Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia, Canada (?Parent?), and Bausch + Lomb Corporation, a company incorporated under the laws of Canada (?Spin

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 28, 2022 Date of Report (Date of the earliest event reported) Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Inc

REDACTED ARRANGEMENT AGREEMENT BAUSCH HEALTH COMPANIES INC. - AND - BAUSCH + LOMB CORPORATION - AND - 1261229 B.C. LTD. - AND - 12279967 CANADA LTD. - AND - 12283778 CANADA LTD. Made as of April 28, 2022

Exhibit 99.1 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. ARRANGEMENT AGREEMENT BETWEEN BAUSCH HEALTH COMPANIES INC. - AND - BAUSCH + LOMB CORPORATION - AND - 1261229 B.C. LTD. - AND - 12279967 CANADA LTD. - AND - 12283778 CANADA LTD. Made as

AMENDMENT TO TAX MATTERS AGREEMENT

EX-99.3 4 d283951dex993.htm EX-99.3 Exhibit 99.3 AMENDMENT TO TAX MATTERS AGREEMENT This AMENDMENT NO. 1 TO TAX MATTERS AGREEMENT, dated as of April 28, 2022 (this “Amendment”), is by and between Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia, Canada (“Parent”), and Bausch + Lomb Corporation, a company incorporated under the laws of Canada

Regulation FD Disclosure

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): April 25, 2022 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation or

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 18, 2022 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorp

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 4, 2022 (April 1, 2022) Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdic

REDACTED Certain identified information, indicated by [*****], has been excluded from the TAX MATTERS AGREEMENT BAUSCH HEALTH COMPANIES INC., on behalf of itself and the members of the Parent Group BAUSCH + LOMB CORPORATION, on behalf of itself and t

Exhibit 99.3 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. TAX MATTERS AGREEMENT between BAUSCH HEALTH COMPANIES INC., on behalf of itself and the members of the Parent Group and BAUSCH + LOMB CORPORATION, on behalf of itself and the members of

REDACTED it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. TRANSITION SERVICES AGREEMENT BY AND BETWEEN BAUSCH HEALTH COMPANIES INC. BAUSCH + LOMB CORPORATION Dated as of March 30, 2022

Exhibit 99.2 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. TRANSITION SERVICES AGREEMENT BY AND BETWEEN BAUSCH HEALTH COMPANIES INC. AND BAUSCH + LOMB CORPORATION Dated as of March 30, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE

REDACTED Certain identified information, indicated by [*****], has been excluded from the INTELLECTUAL PROPERTY MATTERS AGREEMENT BY AND BETWEEN BAUSCH HEALTH COMPANIES INC. BAUSCH + LOMB CORPORATION Dated as of March 30, 2022

Exhibit 99.5 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. INTELLECTUAL PROPERTY MATTERS AGREEMENT BY AND BETWEEN BAUSCH HEALTH COMPANIES INC. AND BAUSCH + LOMB CORPORATION Dated as of March 30, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS

REDACTED REAL ESTATE MATTERS AGREEMENT

Exhibit 99.6 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. REAL ESTATE MATTERS AGREEMENT This REAL ESTATE MATTERS AGREEMENT, dated as of March 30, 2022 (this ?Agreement?), is by and between Bausch Health Companies Inc., a corporation continued

REDACTED REGISTRATION RIGHTS AGREEMENT

EX-99.7 8 d338836dex997.htm EX-99.7 Exhibit 99.7 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT, dated as of March 30, 2022 (this “Agreement”), is made by and between Bausch Health

EMPLOYEE MATTERS AGREEMENT by and between BAUSCH HEALTH COMPANIES INC. BAUSCH + LOMB CORPORATION Dated as of March 30, 2022

EX-99.4 5 d338836dex994.htm EX-99.4 Exhibit 99.4 EMPLOYEE MATTERS AGREEMENT by and between BAUSCH HEALTH COMPANIES INC. and BAUSCH + LOMB CORPORATION Dated as of March 30, 2022 TABLE OF CONTENTS PAGE ARTICLE I DEFINITIONS Section 1.01. Certain Definitions 1 ARTICLE II GENERAL ALLOCATION OF LIABILITIES; INDEMNIFICATION Section 2.01. Allocation of Employee-Related Liabilities 9 Section 2.02. Indemni

REDACTED MASTER SEPARATION AGREEMENT BY AND BETWEEN BAUSCH HEALTH COMPANIES INC. BAUSCH + LOMB CORPORATION Dated as of March 30, 2022

Exhibit 99.1 REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. MASTER SEPARATION AGREEMENT BY AND BETWEEN BAUSCH HEALTH COMPANIES INC. AND BAUSCH + LOMB CORPORATION Dated as of March 30, 2022 TABLE OF CONTENTS Page SCHEDULES iv EXHIBITS iv ARTICLE

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 30, 2022 Date of Report (Date of the earliest event reported) Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Inc

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 14, 2022 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of incorp

BAUSCH HEALTH COMPANIES INC. ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2021 RESULTS AND PROVIDES 2022 GUIDANCE

Exhibit 99.1 Investor Contact: Media Contact: Arthur Shannon Lainie Keller [email protected] [email protected] (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES INC. ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2021 RESULTS AND PROVIDES 2022 GUIDANCE ?Fourth-Quarter 2021 Financial Results ?Revenues of $2.196 Billion ?GAAP Net Income of $69 Millio

Subsidiaries of Bausch Health Companies Inc.

EX-21.1 3 exhibit2112021ye.htm EX-21.1 Exhibit 21.1 Subsidiary Information As of February 23, 2022 Company Jurisdiction of Incorporation Doing Business As Bausch & Lomb Argentina S.R.L. Argentina Bausch & Lomb Argentina S.R.L. Waicon Vision S.A. Argentina Waicon Vision S.A. Bausch & Lomb (Australia) Pty Limited Australia Bausch & Lomb (Australia) Pty Limited Bausch Health Australia Pty Limited Aus

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 23, 2022 Date of report (Date of earliest event reported) Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 001-14956 98-0448205 (State or other jurisdiction of inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Companies I

Amended and Restated Employment Agreement, dated February 18, 2022, between Bausch Health Companies Inc. and Thomas Appio, originally filed as Exhibit 10.20 on the Company’s Annual Report on Form 10-K filed on February 23, 2022, which is incorporated by reference herein. †

Exhibit 10.20 BAUSCH HEALTH COMPANIES INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is hereby entered into as of February 18, 2022, by and between Bausch Health Companies Inc., a company incorporated in the Province of British Columbia, Canada (together with any successor thereto, ?Bausch Health? or the ?Company?), and Thomas J. Appio, an individual (th

BHC / BauschHealth?Companies?Inc. / NOMURA HOLDINGS INC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bausch Health Companies Inc. (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 071734107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

Indenture, dated as of February 10, 2022, by and among Bausch Health Companies Inc., the guarantors named therein, The Bank of New York Mellon, N.A., as trustee and the notes collateral agents party thereto, governing the 6.125% Senior Secured Notes due 2027, originally filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on February 10, 2022, which is incorporated by reference herein.

Exhibit 4.1 Execution Version BAUSCH HEALTH COMPANIES INC. $1,000,000,000 6.125% SENIOR SECURED NOTES DUE 2027 INDENTURE DATED AS OF FEBRUARY 10, 2022 THE BANK OF NEW YORK MELLON, AS TRUSTEE, REGISTRAR AND PAYING AGENT AND THE NOTES COLLATERAL AGENTS PARTY HERETO TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.1 Definitions 1 Section 1.2 Other Definitions 31 S

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): February 10, 2022 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-14956 98-0448205 (State or Other Jurisdiction of Incorporation